Scholarlink

Background <p>Emerging evidence has revealed the potential efficacy of Novel Hormonal Agent (NHA) or chemotherapy in high-risk patients with biochemical recurrence (BCR). However, the optimal drug-based treatment strategy remains unknown.</p> Methods <p>We conducted a comprehensive search of the PubMed, Cochrane, and Embase databases up to February 18, 2024 to identify relevant studies. Our analysis focused on outcome measures, including prostate-specific antigen progression-free survival (PSA-PFS), overall survival (OS) and the incidence of adverse events (AEs). A Bayesian network meta-analysis was utilized to indirectly compare the efficacy and safety of various treatment modalities.</p> Results <p>Four randomized controlled trials with 2074 participants were selected for data extraction and analysis. Treatment combining Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) significantly enhanced PSA-PFS as compared to ADT monotherapy (Hazard Ratio (HR) = 0.07, 95% Confidence Interval (CI) 0.01–0.97). The surface under the cumulative ranking curve (SUCRA) indicated ADT + ENZA as the most effective strategy for improving PSA-PFS. In terms of OS improvement, the treatments were ranked as follows: ADT + Docetaxel (DOC), ADT + ENZA, ENZA, and ADT. In terms of adverse event incidence, ADT exhibited the lowest incidence of adverse events, followed by ADT + ENZA. In the meta-analysis, ADT + NHA combined therapy achieved superior efficacy in PSA-PFS and OS than ADT.</p> Conclusion <p>This study suggests that ADT + NHA, particularly ADT + ENZA, may provide a significant survival benefit and an acceptable safety profile for prostate cancer patients at high-risk BCR. The findings could potentially inform the selection of medications for these patients, although further confirmation through large-scale clinical trials is imperative.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Drug treatment options of high-risk biochemically recurrent prostate cancer based on efficacy and safety: a systematic review and Bayesian network analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月6日

查看全文
  • Qian Wang,
  • Qiyu Zhu,
  • Haoyang Liu,
  • Ke Huang,
  • Xingming Zhang,
  • Jinge Zhao,
  • Hong Zeng,
  • Jindong Dai,
  • Yifu Shi,
  • Hao Zeng,
  • Pengfei Shen

摘要

Background

Emerging evidence has revealed the potential efficacy of Novel Hormonal Agent (NHA) or chemotherapy in high-risk patients with biochemical recurrence (BCR). However, the optimal drug-based treatment strategy remains unknown.

Methods

We conducted a comprehensive search of the PubMed, Cochrane, and Embase databases up to February 18, 2024 to identify relevant studies. Our analysis focused on outcome measures, including prostate-specific antigen progression-free survival (PSA-PFS), overall survival (OS) and the incidence of adverse events (AEs). A Bayesian network meta-analysis was utilized to indirectly compare the efficacy and safety of various treatment modalities.

Results

Four randomized controlled trials with 2074 participants were selected for data extraction and analysis. Treatment combining Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) significantly enhanced PSA-PFS as compared to ADT monotherapy (Hazard Ratio (HR) = 0.07, 95% Confidence Interval (CI) 0.01–0.97). The surface under the cumulative ranking curve (SUCRA) indicated ADT + ENZA as the most effective strategy for improving PSA-PFS. In terms of OS improvement, the treatments were ranked as follows: ADT + Docetaxel (DOC), ADT + ENZA, ENZA, and ADT. In terms of adverse event incidence, ADT exhibited the lowest incidence of adverse events, followed by ADT + ENZA. In the meta-analysis, ADT + NHA combined therapy achieved superior efficacy in PSA-PFS and OS than ADT.

Conclusion

This study suggests that ADT + NHA, particularly ADT + ENZA, may provide a significant survival benefit and an acceptable safety profile for prostate cancer patients at high-risk BCR. The findings could potentially inform the selection of medications for these patients, although further confirmation through large-scale clinical trials is imperative.